Sutro Biopharma (STRO) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Sutro Biopharma is scheduled to release its Q2 2025 quarterly earnings on Tuesday, August 12th, with analysts predicting a loss of ($0.53) per share and revenue of $14.55 million.
• The company reported a loss of ($0.91) per share in its previous earnings announcement, which was below analysts' expectations of ($0.63), despite revenue exceeding estimates.
• Institutional investors own 96.99% of Sutro Biopharma, with notable increases in stakes by firms like AQR Capital Management, which raised its stake by 1,052.8%.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $14.55 million for the quarter.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.28). Sutro Biopharma had a negative net margin of 373.66% and a negative return on equity of 347.60%. The business had revenue of $17.40 million during the quarter, compared to the consensus estimate of $11.61 million. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Stock Down 1.7%

Sutro Biopharma stock traded down $0.01 during midday trading on Thursday, reaching $0.80. The stock had a trading volume of 75,069 shares, compared to its average volume of 1,313,277. The firm has a market capitalization of $67.91 million, a PE ratio of -0.27 and a beta of 1.66. Sutro Biopharma has a 12 month low of $0.52 and a 12 month high of $5.17. The firm's 50-day moving average price is $0.81 and its 200 day moving average price is $1.06.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Bank of America decreased their target price on Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating on the stock in a research note on Monday, May 19th. HC Wainwright restated a "neutral" rating and issued a $2.00 target price on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Finally, Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price target on the stock in a research note on Monday, June 16th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $6.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its position in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after acquiring an additional 1,206,330 shares in the last quarter. Strs Ohio purchased a new position in Sutro Biopharma during the 1st quarter worth $99,000. Finally, Invesco Ltd. increased its holdings in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company's stock valued at $60,000 after acquiring an additional 53,390 shares in the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.